PLoS ONE (Jan 2014)

Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey.

  • Clara Natoli,
  • Davide Brocco,
  • Isabella Sperduti,
  • Antonio Nuzzo,
  • Nicola Tinari,
  • Michele De Tursi,
  • Antonino Grassadonia,
  • Lorenzo Mazzilli,
  • Stefano Iacobelli,
  • Teresa Gamucci,
  • Patrizia Vici,
  • “FOLLOW-UP” Study Group

DOI
https://doi.org/10.1371/journal.pone.0094063
Journal volume & issue
Vol. 9, no. 4
p. e94063

Abstract

Read online

PurposeBreast cancer follow-up procedures after primary treatment are still a controversial issue. Aim of this study was to investigate, through a web-based survey, surveillance methodologies selected by Italian oncologists in everyday clinical practice.MethodsReferents of Italian medical oncology units were invited to participate to the study via e-mail through the SurveyMonkey website. Participants were asked how, in their institution, exams of disease staging and follow-up are planned in asymptomatic women and if surveillance continues beyond the 5th year.ResultsBetween February and May 2013, 125 out of 233 (53.6%) invited referents of Italian medical oncology units agreed to participate in the survey. Ninety-seven (77.6%) referents state that modalities of breast cancer follow-up are planned according to the risk of disease progression at diagnosis and only 12 (9.6%) oncology units apply the minimal follow-up procedures according to international guidelines. Minimal follow-up is never applied in high risk asymptomatic women. Ninety-eight (78.4%) oncology units continue follow-up in all patients beyond 5 years.ConclusionsOur survey shows that 90.4% of participating Italian oncology units declare they do not apply the minimal breast cancer follow-up procedures after primary treatment in asymptomatic women, as suggested by national and international guidelines. Interestingly, about 80.0% of interviewed referents performs the so called "tailored follow-up", high intensity for high risk, low intensity for low risk patients. There is an urgent need of randomized clinical trials able to determine the effectiveness of risk-based follow-up modalities, their ideal frequency and persistence in time.